Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casimersen Dose-Titration in Advanced DMD
NCT02530905Phase 1Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Oct 2015
- Primary completion
- Oct 2018
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of casimersen in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Sarepta Therapeutics. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Number of Participants With Potentially Clinically Significant Laboratory Abnormalities Reported as TEAEs and 3 more. Started Oct 2015; status: completed.
02
Drugs
casimersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02530905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530905.